natgillin/translations-raw huggingface dataset:
Co-administration of bupropion with drugs that are metabolised by CYP2D6 isozyme including certain antidepressants (SSRIs and many tricyclic antidepressants, e.g. desipramine, imipramine, paroxetine), antipsychotics (e.g., haloperidol, risperidone and thioridazine), beta-blockers (e.g., metoprolol) and Type 1C antiarrhythmics (e.g., propafenone and flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medicinal product. 
Istodobnoj primjeni bupropiona s lijekovima koji se metaboliziraju putem CYP2D6 izoenzima uključujući određene antidepresive (selektivne inhibitore ponovne pohrane serotonina i mnoge tricikličke antidepresive, npr. dezipramin, imipramin, paroksetin), antipsihotike (npr. haloperidol,
Naltrexone / bupropion is contraindicated in patients with end-stage renal failure (see section 4.3). 
Naltrekson / bupropion je kontraindiciran u bolesnika sa završnim stadijem zatajenja bubrega (vidjeti dio 4.3).
Anaphylactoid/anaphylactic reactions characterized by symptoms such as pruritus, urticaria, angioedema, and dyspnoea requiring medical treatment have been reported in clinical trials with bupropion. 
U kliničkim ispitivanjima s bupropionom su prijavljene anafilaktoidne / anafilaktičke reakcije okarakterizirane simptomima kao što su pruritus, urtikarija, angioedem, i dispneja koji su zahtijevali liječenje.
The effects of cigarette smoking on the pharmacokinetics of bupropion were studied in 34 healthy male and female volunteers; 17 were chronic cigarette smokers and 17 were nonsmokers. 
Učinci pušenja cigareta na farmakokinetiku bupropiona su ispitivani u 34 zdravih ženskih i muških dobrovoljaca; 17 su bili kronični pušači cigareta a nepušača je bilo 17. Nakon peroralne primjene jedne doze od 150 mg bupropionklorida, nije bilo statistički značajne razlike u Cmax, poluvijeku, Tmax, AUC ili klirensu bupropiona ili njegovih aktivnih metabolitima između pušača i nepušača.
Since bupropion is extensively metabolised, caution is advised when naltrexone / bupropion is co-administered with medicinal products known to induce CYP2B6 (e.g., carbamazepine, phenytoin, ritonavir, efavirenz) as these may affect the clinical efficacy of naltrexone / bupropion. 
Budući da se bupropion opsežno metabolizira, potreban je oprez kada se naltrekson / bupropion primjenjuju istodobno s lijekovima za koje se zna da induciraju CYP2B6 (npr. karbamazepin, fenitoin,
Uncommon Postural hypotension (B), Vasodilatation (B) 
Krvožilni poremećaji manje često posturalna hipotenzija (B), vazodilatacija (B)
Naltrexone / bupropion has not been extensively evaluated in subjects with renal insufficiency. 
Naltrekson / bupropion nije opsežno ocijenjen u ispitanika s insuficijencijom bubrega.
Fits (seizures) 
- koprivnjača (urtikarija)
Taste disorders (B) 
Klasifikacija organskih sustava Učestalost Nuspojava (B)
Drug induced liver injury 
Bolesnici s oštećenjem jetre
Metabolism and Nutrition Disorders 
Poremećaji metabolizma i prehrane rijetko dehidracija
• Patients currently dependent on chronic opioids (see sections 4.4 and 4.5) or opiate agonists 
• Bolesnici trenutno ovisni o kroničnoj primjeni opioida (vidjeti dijelove 4.4 i 4.5) ili agonistima opijata (npr. metadon) ili bolesnici u akutnom ustezanju od opijata • Bolesnici koji primaju istodobno inhibitore monoaminooksidaze (MAOI).
- if you have a condition that causes fits (seizures) or if you have a history of fits; - if you have a brain tumour; - if you are usually a heavy drinker and you have just stopped drinking alcohol, or are going to stop while you are taking Mysimba; - if you have recently stopped taking sedatives or medicines to treat anxiety (especially benzodiazepines), or if you are going to stop them while you are taking Mysimba; - if you have a bipolar disorder (extreme mood swings); - if you are using any other medicines which contain bupropion or naltrexone; - if you have an eating disorder or had one in the past (for example, bulimia or anorexia nervosa); - if you are currently dependent on chronic opiates or opiate agonists (for example methadone), or you are going through acute withdrawal (cold turkey); - if you are taking medicines for depression or Parkinson's disease called monoamine oxidase inhibitors (MAOIs) or have taken them in the last 14 days; - if you have severe liver disease; - if you have endstage kidney disease. 
ili prolazite kroz akutno ustezanje; - ako uzimate lijekove za depresiju ili Parkinsonovu bolest pod nazivom inhibitori monoaminooksidaze (MAOI), ili ste ih uzeli u posljednjih 14 dana; - ako imate tešku bolest jetre; - ako imate završni stadij bolesti bubrega.
Early, transient mean increases from baseline in systolic and diastolic blood pressure of up to 1 mmHg were observed in naltrexone / bupropion Phase 3 clinical trials. 
U kliničkim ispitivanjima faze 3 s naltrekson /bupropionom opaženo je rano, prolazno povišenje srednje vrijednosti sistoličkog i dijastoličkog krvnog tlaka u odnosu na početne vrijednosti do 1 mmHg.
Blood and Lymphatic System Disorders Rare 
Poremećaji krvi i limfnog sustava rijetko smanjen hematokrit, smanjen broj limfocita nepoznato limfadenopatija
Submission of final study report by 31 
Dostaviti konačno izvješće ispitivanja do 31. ožujka 2022.
There is no experience with the use of forced diuresis, dialysis, hemoperfusion, or exchange transfusion in the management of combined use of bupropion and naltrexone overdoses. 
hemoperfuzije ili zamjenske transfuzije u liječenju predoziranja kombinirane uporabe bupropiona i naltreksona.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients Tablet core: 
PRILOG I. SAŽETAK OPISA SVOJSTAVA LIJEKA
In patients with mild hepatic impairment, the maximum recommended daily dose for naltrexone / bupropion should be reduced, as these patients may have higher drug concentrations which could result in an increase in adverse drug reactions. 
U bolesnika s blagim oštećenjem jetre, najviša preporučena dnevna doza za naltrekson / bupropion mora se smanjiti jer ti bolesnici mogu imati više koncentracije lijeka što bi moglo rezultirati povećanjem učestalosti nuspojava (vidjeti dijelove 4.2 i 5.2).
Naltrexone (100 mg/kg/day, approximately 30 times the dose of naltrexone in naltrexone/bupropion on a mg/m2 basis) caused a significant increase in pseudo-pregnancy in the rat. 
Naltrekson (100 mg / kg / dan, otprilike 30 puta veća doza od doze naltreksona u naltrekson /
Post Authorisation Safety Study : 
Ispitivanje sigurnosti primjene lijeka nakon dobivanja odobrenja za stavljanje lijeka u promet:
System Organ Class 
MedDRA - klasifikacije organskih sustava
What Mysimba looks like and contents of the pack Mysimba prolonged-release tablets are blue, biconvex, round tablets debossed with “NB-890” on one side. 
Lijek Mysimba tablete s produljenim oslobađanjem su plave, bikonveksne, okrugle tablete s utisnutim
Naltrexone 
Naltrekson
Uncommon Hypersensitivity, Urticaria Rare 
Poremećaji imunološkog sustava manje često reakcije preosjetljivosti, urtikarija rijetko angiodem
Anxiety, Insomnia 
- smetenost, dezorijentiranost
A patient with suspected DILI should stop taking naltrexone / bupropion. 
Bolesnik kod kojeg se sumnja na oštećenje jetre uzrokovano lijekovima mora prekinuti uzimati naltrekson / bupropion.
Uncommon side effects (may affect up to 1 in 100 people): - Hives (uticaria) - Hypersensitivity - Abnormal dreams, - Feeling nervous, feeling spacey, tension, agitation, mood swings, Tremor of the head or a limb which increases when trying to perform a particular function (intention tremor) - Balance disorder - Loss of memory (amnesia), Tingling or numbness of the hands or feet - Motion sickness - Burping - Abdominal discomfort - Indigestion - Inflammation of the gallbladder (cholecystitis) - Increased creatinine levels in the blood (indicating loss of kidney function) - Increased liver enzymes and bilirubin levels, liver disorders - Difficulty in getting or keeping an erection - Feeling abnormal, weakness (asthenia) - Thirst, feeling hot - Chest pain - Increased appetite, weight gain 
- upala žučnog mjehura (kolecistitis) - povećana razina kreatinina u krvi (što znači gubitak funkcije bubrega) - povećane razine jetrenih enzima i bilirubina, poremećaji jetre - poteškoće postizanja ili održavanja erekcije - osjećaj abnormalnosti, slabost (astenija) - žeđ, osjećaj vrućine
Limited clinical data suggest a higher incidence of adverse reactions (e.g., nausea, vomiting, and neuropsychiatric adverse reactions - see section 4.8) in patients receiving bupropion concurrently with either levodopa or amantadine. 
povraćanje, i neuropsihijatrijske nuspojave - vidjeti dio 4.8) u bolesnika koji primaju bupropion istodobno s bilo levodopom ili amantadinom.
CYP2B6 inducers, inhibitors and substrates 
CYP2B6 induktori, inhibitori i supstrati Bupropion se metabolizira u svoj glavni aktivni metabolit hidroksibupropion prvenstveno preko
Respiratory, Thoracic and Mediastinal Disorders 
Učinak na kardiovaskularne i metaboličke parametre
Fatigue, Feeling jittery, Irritability Uncommon Asthenia, Feeling abnormal, Feeling hot, Increased appetite, Thirst 
Opći poremećaji i reakcije na mjestu primjene često umor, osjećaj nervoze, razdražljivost manje često astenija, abnormalni osjećaj, osjećaj vrućine, povećan apetit, žeđ rijetko bol u prsištu, periferna hladnoća, pireksija nepoznato zimica, povećana energija
Prolonged-release tablet. 
Tableta s produljenim oslobađanjem
Not known side effects (frequency cannot be estimated from the available data): - Swollen glands in the neck, armpit or groin (lymphadenopathy) - Mood disorders - Irrational ideas (delusions) - Psychosis - Loss of sexual desire - Feeling hostile - Severe suspiciousness (paranoia) - Aggression - Attention disturbance - Nightmares - Confusion, disorientation - Memory impairment - Restlessness - Muscle stiffness, uncontrolled movements, problems with walking or coordination - Blurred vision, eye pain, eye irritation, eye swelling, watery eyes, increased sensitivity to light 
Poremećaji živčanog sustava vrlo često glavobolja često omaglica, tremor, disgeuzija, letargija, somnolencija manje često intencijski tremor, poremećaj ravnoteže, amnezija rijetko gubitak svijesti, parestezija, presinkopa, napadaj**, sinkopa nepoznato distonija, gubitak pamćenja, parkinsonizam, nemir
Uncommon Cholecystitis, ALT increased, AST increased, Hepatic enzyme increased 
Poremećaji jetre i žuči manje često kolecistitis, povišen ALT, povišen AST, povišeni jetreni enzimi rijetko oštećenje jetre uzrokovano lijekovima nepoznato hepatitis
Micturition urgency 
Prijavljivanje nuspojava
Uncommon Blood bilirubin increased (N), Jaundice (B) 
Poremećaji jetre i žuči manje često povišen bilirubin u krvi (N) žutica (B)
Hepatic impairment 
- osjećaj nervoze
Titanium dioxide (E171) Macrogol 3350 
Filmska ovojnica: poli(vinilni alkohol) titanijev dioksid (E171) makrogol 3350 talk indigo carmine aluminium lake (E132)
PharmaSwiss EOOD Teл. 
Valeant Pharma Magyarország Kft.
Valeant Pharma Magyarország Kft. Tel: 06 8 010 9471 
PharmaSwiss d.o.o. Tel: 0800 81 944
Very Common Nausea, Constipation, Vomiting Common 
- grlobolja, poremećaj glasa, kašalj, zijevanje
Vascular disorders 
vulvovaginalna suhoća
(angioedema) - Excessive loss of body water (dehydration) - Hallucinations - Fainting, almost fainting (presyncope), loss of consciousness - Fits - Passage of fresh blood through the anus usually in or with stool (haematochezia) - Projection of an organ or the tissue encompassing an organ through the wall of the cavity that normally contains it (hernia) - Toothache - Dental caries, cavities - Pain in the lower part of the abdomen - Injury to the liver due to drug toxicity - Jaw pain - A disorder characterised by a sudden compelling urge to urinate (micturition urgency) - Irregular menstrual cycle, vaginal bleeding, dryness of the female vulva and vagina 
Poremećaji probavnog sustava vrlo često mučnina, zatvor, povraćanje često suha usta, bol u gornjem dijelu abdomena, bol u abdomenu manje često neugoda u abdomenu, dispepsija, podrigivanje rijetko hematohezija, hernija, oticanje usana, bol u donjem dijelu abdomena, zubni karijes***, zubobolja***
Dysuria, Pollakiuria, Urinary frequency and/or retention Reproductive System and Breast Disorders Uncommon Erectile dysfunction Rare 
Poremećaji reproduktivnog sustava i dojki često odgođena ejakulacija (N)
Monoamine oxidase inhibitors (MAOI) 
Budući da inhibitori monoaminooksidaze
Oral use. 
PR) primijenjenih samostalno.
The company wanted the authorisation to be recognised in Germany (the ‘concerned Member State'). 
Tvrtka je željela da odobrenje bude priznato u Njemačkoj („uključena država članica”).
On 25 July 2013, the European Medicines Agency completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the medicine Methylphenidate Hexal. 
Europska agencija za lijekove dovršila je 25. srpnja 2013. postupak arbitraže nakon neslaganja između država članica Europske unije (EU) u svezi izdavanja odobrenja za lijek Methylphenidate Hexal.
What is Methylphenidate Hexal? 
Što je Methylphenidate Hexal?
Why was Methylphenidate Hexal reviewed? 
Zašto je Methylphenidate Hexal ispitan?
Hexal A/S submitted Methylphenidate Hexal for mutual recognition on the basis of the initial authorisation granted by Denmark on 29 March 2012 and also valid through a decentralised procedure in Ireland. 
Hexal za postupak međusobnog priznavanja na temelju početnog odobrenja kojeg Danska dala 29. ožujka 2012. godine, a koje također vrijedi i kroz decentralizirani postupak u Irskoj.
Methylphenidate Hexal is a generic medicine based on a ‘reference medicine', Concerta, which is authorised in all the EU Member States. 
Methylphenidate Hexal je generički lijek koji se temelji na „referentnom lijeku” Concerta koji je odobren u svim državama članicama EU-a.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the failure to show bioequivalence between Methylphenidate Hexal and its reference medicine in the immediate-release phase under fed conditions were due to differences between patients in the effects of a high-fat meal on the way medicines are handled by the body, and not to differences between the formulations of the two medicinal products, and that bioequivalence to the reference medicinal product has been shown. 
Na temelju procjene trenutačno dostupnih podataka i znanstvenih rasprava unutar Povjerenstva, CHMP je zaključio da je neuspjeh u dokazivanju bioekvivalencije između Methylphenidate Hexala i njegovog referentnog lijeka u fazi neposrednog otpuštanja, u uvjetima kad je ispitanicima bilo dozvoljeno konzumiranje hrane, bio uzrokovan razlikama između bolesnika u učinku punomasnog obroka na način rukovanja lijekovima od strane tijela, a ne razlikama između formulacija između dva lijeka i da je bioekvivalencija s referentnim lijekom dokazana.
The grounds for the referral were objections raised by Germany and the Netherlands who considered that the bioequivalence study carried out under fed conditions did not show that Methylphenidate Hexal was bioequivalent for the immediate-release phase to its reference product. 
Razlozi za procjenu bili su protivljenja koja su iznijela Njemačka i Nizozemska koje su smatrale da ispitivanje bioekvivalencije provedeno u uvjetima kad su se ispitanici smjeli hraniti nije pokazalo da je Methylphenidate Hexal bioekvivalentan svom referentnom lijeku u fazi neposrednog otpuštanja.
The CHMP therefore concluded that the benefits of Methylphenidate Hexal outweigh its risks and recommended that the marketing authorisation be granted in the concerned Member States. 
CHMP je stoga zaključio da koristi Methylphenidate Hexal nadmašuju njegove rizike i preporučio izdavanje odobrenja za stavljanje lijeka u promet u uključenim državama članicama.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Methylphenidate Hexal outweigh its risks, and the marketing authorisation granted in Denmark can be recognised in other Member States of the EU. 
Povjerenstvo Agencije za humane lijekove (CHMP) zaključilo je da koristi lijeka Methylphenidate Hexal nadmašuju njegove rizike i da se odobrenje za stavljanje lijeka u promet, koje je dala Danska, može prihvatiti u drugim državama članicama EU-a.
Questions and answers on Methylphenidate Hexal (methylphenidate hydrochloride, prolonged-release tablet 18, 36 and 54 mg) EMA/444166/2013 rev.1 
Telefon +44 (0)20 7418 8400 Telefaks +44 (0)20 7418 8416 E-pošta info@ema.europa.eu Web stranica www.ema.europa.eu© European Medicines Agency, 2013.
Questions and answers on Methylphenidate Hexal (methylphenidate hydrochloride, prolonged-release tablet 18, 36 and 54 mg) 
Hexal A/S predao je dokumentaciju za Methylphenidate
Be patient. 
Budite strpljivi.
A: We recommend no longer than one hour. 
O: Preporučuje se ne dulje od sat vremena.
Do not use alcohol. 
Nemojte koristiti alkohol.
The results of both studies were similar. 
Rezultati oba ispitivanja bili su slični.
< PC: {number} SN: {number} NN: {number} 
PC: {broj} SN: {broj} NN: {broj}
A drop of blood may appear. 
Može se pojaviti kapljica krvi.
Repeat steps 8 and 9 until it appears. 
Ponovite korake 8 i 9 dok se ne pojavi kapljica.
Personality changes or abnormal behaviour. 
Promjene osobnosti ili nenormalno ponašanje.
Then the doctor can increase the dose depending on your response. 
Potom liječnik može povećati dozu ovisno o Vašem odgovoru.
This happens generally in patients who grow rapidly. 
To se općenito događa u bolesnika koji brzo rastu.
A: To maintain its strength. 
O: Da bi se očuvala njegova jačina.
No animal data are available. 
Nisu dostupni podaci za životinje.
Part IV: Commonly Asked Questions 
Dio IV: Često postavljana pitanja
Thus, the risk for humans is unknown. 
Stoga, potencijalni rizik za ljude nije poznat.
See also section “warning and precautions”. 
Vidjeti također dio „upozorenja i mjere opreza“.
The greatest risk is at the beginning of treatment. 
Najveći je rizik na početku liječenja.
Always use the needles recommended. 
Uvijek koristite preporučene igle.
Now you are ready to administer the dose. 
Sada ste spremni primijeniti dozu.
This can start during adult life or continue from when you were a child. 
To stanje može početi u odrasloj dobi ili se nastaviti od Vašeg djetinjstva.
Treatment is symptomatic and supportive. 
Liječenje je simptomatsko i suportivno.
• Avoid excessive temperatures. 
• Izbjegavajte prekomjerne temperature.
Do not change the dosage without consulting your doctor. 
Nemojte mijenjati dozu bez savjetovanja s liječnikom.
• You may remove the pen and cartridge from the refrigerator up to 45 minutes prior to use. 
• Možete izvaditi brizgalicu i uložak iz hladnjaka do 45 minuta prije uporabe.
• if you have an active tumour (cancer). 
• ako imate aktivni tumor (rak).
In older or overweight patients, lower doses may be necessary. 
U starijih ili pretilih bolesnika, mogu biti potrebne niže doze.
In general, the lowest efficacious dose should be administered. 
Općenito treba primjenjivati najnižu učinkovitu dozu.
The clinical significance of this decrease is unknown. 
Klinički značaj ovog pada nije poznat.
Avoid areas of extreme temperature. 
Izbjegavajte područja s ekstremnom temperaturom.
(Be careful not to touch the rubber seal.) 
(Pazite da ne dodirujte gumeni čep).
Part I: Preparing and Injecting 
Dio I: Priprema i ubrizgavanje
It is recombinant, meaning it is made outside of the body by a special process. 
To je rekombinantni hormon što znači da se dobiva izvan tijela posebnim procesom.
The working of the pen and the content of the cartridges are the same for both designs. 
Funkcioniranje brizgalice i sadržaj uložaka isti su za oba dizajna.
Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. 
S obzirom da se te reakcije prijavljuju dobrovoljno u populaciji neodređene veličine, nije moguće pouzdano procijeniti njihovu učestalost.
Pack sizes of 1, 3 and 6 cartridges. 
Veličine pakiranja od 1, 3 i 6 uložaka.
• in children if the bones have already stopped growing. 
• kod djece, ako su kosti već prestale rasti.
Always use this medicine exactly as your doctor or pharmacist has told you. 
Uvijek primijenite ovaj lijek točno kako Vam je rekao Vaš liječnik ili ljekarnik.
No data for other races are available. 
Nisu dostupni podaci za druge rase.
Tell your doctor if you have or have had an active tumour. 
Obavijestite svog liječnika ako imate ili ste imali aktivni tumor.
• if you are allergic to somatropin or any of the other ingredients of this medicine (listed in section 6). 
• ako ste alergični na somatropin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
A: No. 
O: Ne.
The maximum recommended daily dose should not be exceeded (see section 4.2). 
Maksimalna preporučena dnevna doza ne smije se premašiti (vidjeti dio 4.2).
The needle is only sterile on the first use. 
Igla je sterilna samo tijekom prve uporabe.
Q: Why do I keep my medication in the refrigerator? 
P: Zašto moram držati svoj lijek u hladnjaku?
DO NOT INJECT THE MEDICINE UNTIL YOUR DOCTOR OR NURSE HAS THOROUGHLY TRAINED YOU IN THE PROPER TECHNIQUES. 
NEMOJTE UBRIZGAVATI LIJEK SVE DOK VAS LIJEČNIK ILI MEDICINSKA SESTRA NISU TEMELJITO OBUČILI TEHNIKAMA PRAVILNOG UBRIZGAVANJA.
If you travel outside the European Union, make sure you take enough needles for the duration of your stay. 
Ako putujete izvan Europske unije, pobrinite se da uzmete dostatan broj igala za cijelo vrijeme Vašeg boravka.
A: Yes. 
O: Da.
Prader-Willi syndrome 
Prader-Willi sindrom
No conventional reproduction studies were performed. 
Nisu provedena konvencionalna ispitivanja reproduktivnosti.
Doses used in these US based studies are consistent with the US approved dose regimen. 
Doze koje se koriste u ovim ispitivanjima u SAD-u sukladne su s režimom doziranja odobrenim u SAD-u.
Q: What does a blinking “bt‟ mean in the LCD? 
P: Što znači trepereći simbol „bt“ na LCD zaslonu?
• Wash your hands thoroughly with soap and water before using your pen. 
• Temeljito operite ruke sapunom i vodom prije nego počnete koristiti svoju brizgalicu.
Put a plaster on the injection site if you wish. 
Stavite flaster na mjesto ubrizgavanja ako želite.
Date of first authorisation: 16 February 2001 Date of latest renewal: 16 February 2006 
Datum posljednje obnove odobrenja: 16. veljače 2006.
If the medicine does not appear within a few seconds, you may need to push the reset button again. 
Ako se lijek ne pojavi unutar nekoliko sekundi, možda ćete trebati ponovno pritisnuti dugme za resetiranje.
If you accidentally turn it too far, go back one click (0.1 mg). 
Ako ga slučajno okrenete previše, vratite se natrag za jedan klik (0,1 mg).
190 Bath Road Slough, Berkshire 
190 Bath Road Slough, Berkshire SL1 3XE
Small bubbles may remain and will not affect the dose. 
Mali mjehurići mogu zaostati i neće utjecati na dozu.
Scoliosis may progress in any child during rapid growth. 
Skolioza može napredovati kod bilo kojeg djeteta s ubrzanim rastom.
Freezing will damage the pen and medicine. 
Zamrzavanje će oštetiti brizgalicu i lijek.
Q: What should I do if there is not enough solution left in the cartridge for my next dose? 
P: Što moram učiniti ako u ulošku nema dovoljno otopine za moju sljedeću dozu?
Continue with your usual dosage the next day and tell your doctor at your next appointment. 
Nastavite sa svojom uobičajenom dozom sljedećeg dana i recite svom liječniku na sljedećem pregledu da ste propustili dozu.
Q: Is it possible to turn the black dose knob back if I click too many times? 
P: Je li moguće okrenuti crno dugme za doziranju unatrag ako kliknem previše puta?
The incidence of these AEs was also high in the placebo groups. 
Incidencija ovih nuspojava bila je isto visoka i u skupinama koje su primale placebo.
Before using your NutropinAq Pen, please read the following instructions carefully. 
Prije uporabe NutropinAq brizgalice pažljivo pročitajte sljedeće upute.
These events are expected in children and were mild/moderate AEs. 
Ti su događaji bili očekivani kod djece i bili su blage/umjerene prirode.
• When you have Turner syndrome. 
• kada imate Turnerov sindrom.